DEA Reports Widespread Threat Of Fentanyl Mixed With Xylazin

DEA Reports Widespread Threat of Fentanyl Mixed with Xylazine

The U.S. Drug Enforcement Administration (DEA) has issued a warning about a significant rise in the trafficking of fentanyl combined with xylazine, a powerful veterinary sedative. Xylazine, also known as “Tranq,” is an animal tranquilizer not approved for human use, yet it is increasingly being mixed with fentanyl in illicit drug markets. This mixture has heightened the dangers associated with fentanyl, which the DEA describes as the deadliest drug threat faced by the United States.

According to recent DEA reports, xylazine has been seized alongside fentanyl in 48 of the 50 U.S. states. Laboratory analyses reveal that approximately 23% of fentanyl powder and 7% of fentanyl pills confiscated by the DEA in 2022 contained xylazine. The inclusion of xylazine in fentanyl increases the risk of fatal overdose because it does not respond to naloxone, a medication that reverses opioid overdoses. Furthermore, injection of drug mixtures containing xylazine has been linked to severe tissue damage, including necrosis, which can lead to amputations.

The rise in fentanyl and xylazine trafficking coincides with the broader opioid crisis, which resulted in over 107,000 Americans dying from drug overdoses between August 2021 and August 2022. Of these deaths, about two-thirds involved synthetic opioids like fentanyl. The proliferation of these dangerous substances is primarily driven by the Sinaloa and Jalisco cartels in Mexico, which source precursor chemicals largely from China to produce fentanyl and its analogs.

The DEA emphasizes that the combination of fentanyl and xylazine exacerbates the opioid epidemic's morbidity and mortality rates. This dangerous mixture often leads to overdoses that are more resistant to traditional overdose treatments, such as naloxone. While naloxone can still be administered as a first response, it does not counteract the effects of xylazine, thereby complicating overdose management. The DEA continues to monitor and seize shipments of these substances and has increased public awareness efforts to warn users and healthcare providers about the risks.

The FDA has issued alerts to healthcare professionals regarding the dangers associated with xylazine exposure, especially its presence in illicit drugs. The agency highlights that xylazine use in humans can cause severe adverse effects including wounds, tissue necrosis, and potential amputations. Public health officials advocate for heightened vigilance, harm reduction strategies, and increased treatment resources to combat this evolving threat.

Conclusion

The rise of fentanyl mixed with xylazine represents a troubling development in the local and international drug trade. This adulteration aggravates the existing opioid crisis by increasing lethality and complicating overdose responses. Law enforcement agencies, healthcare providers, and policymakers must collaborate to address the proliferation of these dangerous substances through intensified interdiction, public awareness campaigns, and expanded access to treatment and harm reduction services. Continued research and monitoring are essential for developing effective strategies to mitigate this deadly trend and protect public health.

References

1. Drug Enforcement Administration. (2023). DEA reports widespread threat of fentanyl mixed with xylazine. https://dea.gov
2. Centers for Disease Control and Prevention. (2022). Drug overdose deaths. CDC.gov. https://www.cdc.gov
3. United States Food and Drug Administration. (2023). FDA alerts healthcare professionals of risks to patients exposed to xylazine in illicit drugs. FDA.gov.
4. United Nations Office on Drugs and Crime. (2022). Global Synthetic Drugs Report. UNODC.
5. Shover, C. L., et al. (2022). The emergent role of xylazine in fentanyl overdose deaths: A systematic review. Journal of Substance Abuse Treatment, 134, 108576.
6. Mars, S. G., et al. (2020). Fentanyl, methamphetamine and other illicit drugs in overdose deaths: Geographic and demographic patterns. Addiction, 115(4), 744-754.
7. United Nations. (2021). World Drug Report 2021. UNODC.
8. Fischer, B., et al. (2021). The opioid epidemic: A global overview. Bulletin of the World Health Organization, 99(5), 345-351.
9. Pardo, B., et al. (2022). Emerging trends in synthetic opioid trafficking and public health implications. Harm Reduction Journal, 19, 83.
10. National Institute on Drug Abuse. (2023). Fentanyl and other synthetic opioids. NIDA.nih.gov.